Pharmafile Logo
Pharmafocus logo
Advanced Search

gilenya

Showing 5 posts of 35 posts found.

Novartis Gilenya (fingolimod)

Oral MS drug Gilenya launched in the UK

April 19, 2011
Sales and Marketing Novartis, gilenya, multiple sclerosis

Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …

News
Novartis headquarters

First oral MS pill approved in Europe

March 21, 2011
Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis

Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News

Novartis MS drug steals march over Merck rival

January 24, 2011
Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis

Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …

News

Gilenya approved as new frontline MS treatment

September 22, 2010
Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya

Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024